SCHEMBL709683

SCHEMBL709683

O=Cc1ccccc1S(=O)(=O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.62
HTT P42858 1/20 0.62
HTR6 P50406 6/20 0.53
ALDH1A1 P00352 3/20 0.50
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
BLM P54132 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
GFER P55789 1/20 0.43
NPSR1 Q6W5P4 1/20 0.41
TRIM24 O15164 1/20 0.40
TRIM33 Q9UPN9 1/20 0.40
TLR9 Q9NR96 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269853 0.85 ALDH1A1 (0.52) TSHRHTTALDH1A1KMT2AMEN1
SCHEMBL3166437 0.85 HTT (0.47) TSHRHTTHTR6ALDH1A1KMT2A
SCHEMBL1468205 0.85 CYP2D6 (0.50) TSHRHTTHTR6ALDH1A1KMT2A
SCHEMBL5879758 0.85 CYP2C9 (0.55) TSHRHTTALDH1A1KMT2AMEN1
SCHEMBL3974600 0.83 TSHR (0.50) TSHRHTTHTR6ALDH1A1KMT2A
SCHEMBL1136581 0.83 TSHR (0.50) TSHRHTTHTR6ALDH1A1KMT2A
SCHEMBL28245639 0.83 HTR6 (0.55) TSHRHTTHTR6ALDH1A1KMT2A
SCHEMBL26615292 0.82 TSHR (0.61) TSHRHTTHTR6ALDH1A1KMT2A
SCHEMBL16494906 0.81 NFE2L2 (0.49) TSHRHTTHTR6ALDH1A1KMT2A
SCHEMBL16494957 0.81 PKM (0.56) HTTHTR6ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5538596-A Process of making paper ALLIED COLLOIDS LIMITED (GB) 1996-07-23 US claimed
US-20200352921-A1 ARYL-SULFONAMIDE AND ARYL-SULFONE DERIVATIVES AS TRPML MODULATORS CALYGENE BIOTECHNOLGY INC (US) 2020-11-12 US disclosed
CN-106083665-B A method of using aryl sulfonyl benzaldehyde hydrozone to cyclopropane compound open loop 太原理工大学 2018-08-03 CN disclosed
CN-105777781-B Thiazole [4,5 e] thiophene [2,3 b] pyridine derivatives with fluorescent functional and preparation method thereof 中山大学 2017-11-10 CN disclosed
CN-106588935-A Derivative of tetra-substituted pyrrolo [3,2-b] pyrrole and organic electroluminescence device based on same 江南大学 2017-04-26 CN disclosed
CN-106083665-A A kind of use the aryl sulfonyl benzaldehyde hydrozone method to cyclopropane compound open loop 太原理工大学 2016-11-09 CN disclosed
CN-105777781-A Thiazole[4,5-e]thiophene[2,3-b]pyridine type derivative with fluorescent function and preparation method thereof 中山大学 2016-07-20 CN disclosed
WO-2016019588-A1 OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE THE BROAD INSTITUTE, INC. (US) 2016-02-11 WO disclosed
CN-102822163-B Crth2 modulators IRONWOOD PHARMACEUTICALS, INC. (US) 2016-01-20 CN disclosed
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 EP disclosed
CN-101014565-A Diarylsulfones as 5-HT2a antagonists MERCK SHARP & DOHME (GB) 2007-08-08 CN disclosed
EP-1807393-A1 DIARYLSULFONES AS 5-HT2A ANTAGONISTS Merck Sharp & Dohme Limited (GB) 2007-07-18 EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 US disclosed
WO-2006021805-A1 DIARYLSULFONES AS 5-HT2A ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-03-02 WO disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 US disclosed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 CN disclosed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 EP disclosed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200352921-A1 ARYL-SULFONAMIDE AND ARYL-SULFONE DERIVATIVES AS TRPML MODULATORS TRPM6, TRPM2, TRPM5 TSHR 2088/4885HTT 1942/4885HTR6 1250/4885
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B TSHR 286/4885HTT 465/4885HTR6 1/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B TSHR 286/4885HTT 465/4885HTR6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.